Skip to content
Inciteful Med

Biology & Genetics: The "Superglue" of Clotting

Last updated:

Factor XIII (FXIII) acts as the "superglue" of blood clotting by cross-linking fibrin strands to stabilize clots and support wound healing. It is an autosomal recessive condition, meaning severe deficiency requires two mutated genes, while carriers with one gene typically remain asymptomatic.

Key Takeaways

  • • Factor XIII stabilizes blood clots by cross-linking fibrin strands, acting like mortar in a brick wall.
  • • Type A deficiency involves the active enzyme and is more severe, while Type B involves the carrier protein.
  • • The condition follows an autosomal recessive pattern, requiring two mutated genes for severe disease.
  • • Carriers typically have 20-60% factor activity and do not need routine treatment.
  • • Factor XIII is essential for wound healing and preventing delayed bleeding after initial clot formation.

Understanding the biology of Factor XIII (FXIII) helps explain why this condition behaves so differently from other bleeding disorders. In the world of blood clotting, most factors are responsible for creating the initial clot. Factor XIII, however, is responsible for making that clot permanent and strong [1][2].

The “Bricks and Mortar” Analogy

Imagine your body is building a brick wall to stop a leak. Other clotting factors (like Factor VIII or IX) are responsible for gathering and stacking the bricks (fibrin strands) [1]. Without Factor XIII, the bricks are just sitting on top of each other. The wall looks finished, and the leak stops for a moment. However, because there is no mortar (Factor XIII) to hold the bricks together, the wall is unstable [3]. As soon as physical movement or blood pressure pushes against it, the wall collapses, and the bleeding starts again [4][5].

The Structure: Two Parts Working Together

Factor XIII is a complex made of two distinct parts that must work together [6]:

  • Subunit A (The Active Enzyme): This is the “active” part of the glue. It is produced in bone marrow cells and specialized immune cells [7][8]. It is responsible for the actual chemical bonding (cross-linking) of the clot [1].
  • Subunit B (The Carrier Protein): This part is made in the liver [9]. Think of Subunit B as a protective “escort.” It circulates in the blood, carrying Subunit A and protecting it from being cleared out of the body too quickly [7][10].

Types of Deficiency

  • Type A Deficiency (95% of cases): This is the most common and typically the most severe form [11]. Because the active enzyme is missing or broken, the body cannot stabilize clots, leading to serious risks like umbilical or brain bleeds [12][13].
  • Type B Deficiency (Rare): This form is generally milder [14]. Because the “carrier” (Subunit B) is missing, the active enzyme (Subunit A) doesn’t have its protective escort and gets cleared from the blood much faster than normal [15].

Genetics and Carriers: Reducing Anxiety

Factor XIII deficiency follows an autosomal recessive pattern [11]. This means:

  1. A child must inherit two mutated genes (one from each parent) to have the severe form [1][16].
  2. If a child inherits only one mutated gene, they are a carrier (heterozygote).

Carrier Symptoms and Management

Carriers usually have 20% to 60% of normal Factor XIII activity [17][18]. This is enough factor to handle daily life without any problems.

  • No Prophylaxis: Carriers do NOT need monthly preventative infusions [19].
  • Major Challenges: Carriers typically only experience symptoms during “major challenges,” such as a serious injury, major surgery, or childbirth [14][20].
  • Surgical Planning: If a carrier is having surgery, a hematologist may recommend a one-time “on-demand” dose of factor to ensure extra safety during the healing process [21].

What is “Cross-linking”?

When Factor XIII is activated, it performs a chemical process called cross-linking. It creates strong, permanent bonds between fibrin strands [4]. These bonds provide the mechanical strength needed to resist the flow of blood and prevent the body’s natural enzymes from dissolving the clot too early [2][22]. This process is also vital for wound healing, providing a stable “scaffold” for new tissue to grow [23][24].

Frequently Asked Questions

What does Factor XIII do in the clotting process?
Factor XIII acts like "mortar" for blood clots by cross-linking fibrin strands. This chemical process creates strong, permanent bonds that prevent the clot from breaking down too early and provides a stable scaffold for wound healing.
What is the difference between Type A and Type B Factor XIII deficiency?
Type A is the most common and severe form (95% of cases), caused by a lack of the active enzyme (Subunit A). Type B is rarer and milder, caused by a lack of the carrier protein (Subunit B) that protects the enzyme in the bloodstream.
How is Factor XIII deficiency inherited?
It follows an autosomal recessive pattern, meaning a child must inherit two mutated genes (one from each parent) to have the severe form. Individuals who inherit only one mutated gene are carriers.
Do Factor XIII carriers have bleeding symptoms?
Carriers typically have 20% to 60% of normal factor activity and usually do not experience symptoms during daily life. However, they may need medical support during major challenges like surgery, serious injury, or childbirth.
Do carriers need regular preventative treatment?
No, carriers generally do not need monthly preventative infusions (prophylaxis). Treatment is typically only needed "on-demand" for specific events like surgery to ensure proper healing.

Questions for Your Doctor

  • • Does my child have a deficiency in Subunit A or Subunit B?
  • • As a parent and carrier, what is my exact Factor XIII activity percentage?
  • • Do I need 'on-demand' factor replacement for my own upcoming dental work or minor surgery?
  • • Should my other children or my siblings be tested for their carrier status?
  • • Can you explain the specific genetic mutation identified in our family?

Questions for You

  • • Have I or any close relatives ever had 'delayed bleeding' that started a day or two after a procedure like a tooth extraction?
  • • Do I have any thin, pale, or "cigarette-paper" scars from old injuries?
  • • Are there any other family members who have experienced multiple unexplained miscarriages?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    State of the art in factor XIII laboratory assessment.

    Durda MA, Wolberg AS, Kerlin BA

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2018; (57(6)):700-704 doi:10.1016/j.transci.2018.07.006.

    PMID: 30087086
  2. 2

    Why fibrin biomechanical properties matter for hemostasis and thrombosis.

    Feller T, Connell SDA, Ariёns RAS

    Journal of thrombosis and haemostasis : JTH 2022; (20(1)):6-16 doi:10.1111/jth.15531.

    PMID: 34528378
  3. 3

    Recurrent venous thromboembolism patients form clots with lower elastic modulus than those formed by patients with non-recurrent disease.

    Baker SR, Zabczyk M, Macrae FL, et al.

    Journal of thrombosis and haemostasis : JTH 2019; (17(4)):618-626 doi:10.1111/jth.14402.

    PMID: 30725502
  4. 4

    Tissue transglutaminase drives fibrin β-chain cross-linking: a novel fibrin modification observed in patients with trauma.

    Boateng NKK, Wimberley R, Rose J, et al.

    Blood 2026; (147(1)):87-92 doi:10.1182/blood.2025029458.

    PMID: 40983029
  5. 5

    Differential Role of Factor XIII in Acute Myocardial Infarction and Ischemic Stroke.

    Traub J, Weber MS, Frey A

    Biomedicines 2024; (12(3)) doi:10.3390/biomedicines12030497.

    PMID: 38540111
  6. 6

    Genetic landscape in coagulation factor XIII associated defects - Advances in coagulation and beyond.

    Javed H, Singh S, Ramaraje Urs SU, et al.

    Blood reviews 2023; (59()):101032 doi:10.1016/j.blre.2022.101032.

    PMID: 36372609
  7. 7

    Exploring Diverse Coagulation Factor XIII Subunit Expression Datasets: A Bioinformatic Analysis.

    Jamil MA, Singh S, El-Maarri O, et al.

    International journal of molecular sciences 2022; (23(9)) doi:10.3390/ijms23094725.

    PMID: 35563115
  8. 8

    Factor XIII-A in Diseases: Role Beyond Blood Coagulation.

    Dull K, Fazekas F, Törőcsik D

    International journal of molecular sciences 2021; (22(3)) doi:10.3390/ijms22031459.

    PMID: 33535700
  9. 9

    Expression of factor XIII originating from synovial fibroblasts and macrophages induced by interleukin-6 signaling.

    Watanabe H, Mokuda S, Tokunaga T, et al.

    Inflammation and regeneration 2023; (43(1)):2 doi:10.1186/s41232-022-00252-4.

    PMID: 36609460
  10. 10

    Development and Epitope Mapping of Seven Mouse Anti-Human Coagulation Factor XIII-B Subunit Monoclonal Antibodies.

    Osaki T, Magari Y, Souri M, Ichinose A

    Monoclonal antibodies in immunodiagnosis and immunotherapy 2024; (43(5)):135-143 doi:10.1089/mab.2024.0016.

    PMID: 39320988
  11. 11

    Factor XIII deficiency in south of Tunisia.

    Maaloul I, Medhaffer M, Louhichi N, et al.

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2017; (28(6)):485-489 doi:10.1097/MBC.0000000000000649.

    PMID: 28704210
  12. 12

    Dental Management of Factor XIII Deficiency Patients: A Case Series.

    Pai NG, Mehta LK, Padhye NM, Sayed ZM

    International journal of clinical pediatric dentistry 2020; (13(3)):299-302 doi:10.5005/jp-journals-10005-1760.

    PMID: 32903982
  13. 13

    Congenital factor XIII deficiency caused by F13A1 gene mutations presenting with intracranial hemorrhage: a case report.

    Wang H, Yang R, Li J

    Frontiers in pediatrics 2025; (13()):1732065 doi:10.3389/fped.2025.1732065.

    PMID: 41488895
  14. 14

    Factor XIII Deficiency: Laboratory, Molecular, and Clinical Aspects.

    Dorgalaleh A, Jozdani S, Zadeh MK

    Seminars in thrombosis and hemostasis 2025; (51(2)):155-169 doi:10.1055/s-0044-1796673.

    PMID: 39613144
  15. 15

    Reciprocal stabilization of coagulation factor XIII-A and -B subunits is a determinant of plasma FXIII concentration.

    Byrnes JR, Lee T, Sharaby S, et al.

    Blood 2024; (143(5)):444-455 doi:10.1182/blood.2023022042.

    PMID: 37883802
  16. 16

    Exploring factor XIII genetic diversity: a familial approach to inheritance and variation.

    Naz A, Zameer S, Rind HAP, et al.

    Thrombosis journal 2025; (23(1)):109 doi:10.1186/s12959-025-00766-0.

    PMID: 41233847
  17. 17

    Recurrent Intramuscular Hematoma Revealing Moderate Congenital Factor XIII Deficiency.

    Ben Halima N, Riahi S, Mazlout I, et al.

    Cureus 2025; (17(10)):e95841 doi:10.7759/cureus.95841.

    PMID: 41328102
  18. 18

    Heterozygosity in factor XIII genes and the manifestation of mild inherited factor XIII deficiency.

    Singh S, Pezeshkpoor B, Jamil MA, et al.

    Journal of thrombosis and haemostasis : JTH 2024; (22(2)):379-393 doi:10.1016/j.jtha.2023.09.032.

    PMID: 37832789
  19. 19

    A case of life-threatening small intestinal bleeding accompanied by lower coagulation factor XIII activity.

    Murata M, Inatomi O, Ono K, et al.

    Clinical journal of gastroenterology 2020; (13(6)):1178-1182 doi:10.1007/s12328-020-01195-4.

    PMID: 32710383
  20. 20

    Factor XIII deficiency in the Saudi population, an underestimated bleeding risk. Review article and an illustrative case report with dental complications.

    Aljabry M

    The Saudi dental journal 2023; (35(4)):305-309 doi:10.1016/j.sdentj.2023.03.015.

    PMID: 37251713
  21. 21

    A large case series on surgical outcomes in congenital factor XIII deficiency patients in Iran.

    Naderi M, Haghpanah S, Miri-Aliabad G, et al.

    Journal of thrombosis and haemostasis : JTH 2017; (15(12)):2300-2305 doi:10.1111/jth.13872.

    PMID: 29028293
  22. 22

    Molecular Detection of Venous Thrombosis in Mouse Models Using SPECT/CT.

    Dickhout A, Van de Vijver P, Bitsch N, et al.

    Biomolecules 2022; (12(6)) doi:10.3390/biom12060829.

    PMID: 35740954
  23. 23

    Congenital Factor XIII Deficiency With the Presence of Inhibitor: A Case Study.

    Karaman S, Akkaya E, Genc S, et al.

    Journal of pediatric hematology/oncology 2021; (43(1)):e99-e102 doi:10.1097/MPH.0000000000001671.

    PMID: 31764516
  24. 24

    The impact of acquired coagulation factor XIII deficiency in traumatic bleeding and wound healing.

    Kleber C, Sablotzki A, Casu S, et al.

    Critical care (London, England) 2022; (26(1)):69 doi:10.1186/s13054-022-03940-2.

    PMID: 35331308

This guide explains the biology and genetics of Factor XIII deficiency for educational purposes. Always consult your hematologist or genetic counselor for specific medical advice and testing.

Stay up to date

Get notified when new research about Factor XIII Deficiency is published.

No spam. Unsubscribe anytime.